Truist Securities Initiates Coverage of Summit Therapeutics

Dec 23, 2024 · Fintel reports that on January 8, 2025, Truist Securities initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation. As of December 23, …

$35.00
OFF

Truist Starts Summit Therapeutics With Buy Rating On Ivonescimab ...

1 week from now

Jan 8, 2025 · On Wednesday, Truist Securities initiated coverage on Summit Therapeutics plc (NASDAQ: SMMT) stock, assigning a Buy rating and setting a price target of $35.00.The firm's …

investing.com

$35
OFF

Summit Therapeutics Initiated With A Buy At Truist

1 week from now

Jan 8, 2025 · Truist initiated coverage of Summit Therapeutics with a Buy rating and $35 price target Summit is a biotech company built around ivonescimab, the most clinically advanced …

businessinsider.com

71%
OFF

Truist Securities Initiates Coverage Of Summit Therapeutics (SMMT …

1 week from now

Fintel reports that on January 8, 2025, Truist Securities initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation. Analyst Price Forecast Suggests 80.71% …

msn.com

$35.00
OFF

Truist Starts Summit Therapeutics With Buy Rating On Ivonescimab ...

1 week from now

Jan 8, 2025 · On Wednesday, Truist Securities initiated coverage on Summit Therapeutics plc (NASDAQ: SMMT) stock, assigning a Buy rating and setting a price target of $35.00.The firm's …

investing.com

$19.00
OFF

Summit Therapeutics (NASDAQ:SMMT) Research Coverage Started …

1 week from now

5 days ago · Citigroup lowered Summit Therapeutics from a “buy” rating to a “neutral” rating and raised their target price for the company from $19.00 to $23.00 in a report on Friday, …

etfdailynews.com

$35
OFF

Truist Initiates Summit Therapeutics At Buy With $35 Price Target

1 week from now

Jan 8, 2025 · Jefferies Initiates Summit Therapeutics at Buy With $31 Price Target Dec. 06: MT Summit Therapeutics Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 …

marketscreener.com

584%
OFF

Why Summit Therapeutics Rocketed 584% In 2024 | The Motley Fool

1 week from now

2 days ago · Summit Therapeutics' drug Ivonescimab posted positive results in not one but two phase 3 trials during 2024. ... with Truist analyst Asthika Goonewardene recently giving the …

fool.com

4%
OFF

Summit Therapeutics Rises After Truist Starts Coverage With 'buy ...

1 week from now

Jan 8, 2025 · ** Shares of drug developer Summit Therapeutics NASDAQ:SMMT rise ~4% to $18.88** Brokerage Truist Securities starts coverage on SMMT with "buy" rating; PT $35** PT …

tradingview.com

4%
OFF

Summit Therapeutics Shares Jump Following Truist's 'buy' Rating …

1 week from now

Jan 8, 2025 · Shares of Summit Therapeutics (NASDAQ:SMMT), a drug development company, have seen a boost of approximately 4%, reaching $18.88.. This surge follows Truist Securities …

grafa.com

$35
OFF

Truist Initiates Summit Therapeutics With Buy Rating And $35 Price …

1 week from now

Jan 9, 2025 · Summit Therapeutics has been initiated with a Buy rating and $35 price target by Truist. The biotech company is developing ivonescimab, a novel drug class with potential to …

ainvest.com

$35.00
OFF

Truist Starts Summit Therapeutics With Buy Rating On Ivonescimab ...

1 week from now

Jan 8, 2025 · On Wednesday, Truist Securities initiated coverage on Summit Therapeutics plc (NASDAQ: SMMT) stock, assigning a Buy rating and setting a price target of $35.00.The firm’s …

investing.com

584%
OFF

Why Summit Therapeutics Rocketed 584% In 2024 - Yahoo Finance

1 week from now

1 day ago · Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024, according to data from S&P Global Market Intelligence. Summit was an early-stage …

yahoo.com

$35
OFF

Summit Therapeutics Shares Are Trading Higher After Truist …

1 week from now

Jan 8, 2025 · Summit Therapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and a $35 price target.

sahmcapital.com

FAQs about Truist Securities Initiates Coverage of Summit Therapeutics Coupon?

Should you buy Summit Therapeutics (SMMT)?

Truist initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $35 price target Summit is a biotech company built around ivonescimab, the most clinically advanced asset in a novel class of drugs that has potential to surpass the most successful drug class in oncology, the analyst tells investors in a research note. ...

What is the average price target for Summit Therapeutics?

As of December 23, 2024, the average one-year price target for Summit Therapeutics is $34.00/share. The forecasts range from a low of $23.23 to a high of $46.20. The average price target represents an increase of 80.71% from its latest reported closing price of $18.82 / share. See our leaderboard of companies with the largest price target upside. ...

Who owns Summit Therapeutics?

Finally, CIBC Asset Management Inc acquired a new stake in Summit Therapeutics during the second quarter valued at approximately $154,000. 4.61% of the stock is owned by institutional investors. (Get Free Report) ...

Is Stifel Nicolaus a buy on Summit Therapeutics?

Stifel Nicolaus upped their price target on Summit Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. JMP Securities assumed coverage on shares of Summit Therapeutics in a research note on Monday, November 4th. ...

How do I receive news & ratings for Summit Therapeutics?

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. ...

What does Summit Therapeutics do?

(Get Free Report) Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. ...